Patent number: 9890174
Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Type:
Grant
Filed:
December 8, 2014
Date of Patent:
February 13, 2018
Assignee:
UCB BIOPHARMA SPRL
Inventors:
Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu